FOGSI Consensus Redefines Endometriosis Care with Oral GnRH Antagonist, Elagolix Medical Dialogues
Upon exposure to biofluids, engineered nanoparticles (NPs) spontaneously form reproducible biomolecular coronas via selective diverse biomolecule adsorption. The corona characterization of metabolites poses greater analytical challenges than proteins due to …
Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …
For many patients with endometriosis, laparoscopic surgery is the most effective treatment to alleviate severe chronic pelvic pain and improve quality of life. Because endometriosis is common among individuals with …
Endometriosis in a surgical scar is a rare but important clinical phenomenon that can lead to significant morbidity, especially in women with a history of caesarean sections. We present a …
Endometriosis is a chronic inflammatory condition experienced by approximately 10% of women worldwide. Women living with endometriosis experience multidimensional burdens often attributed to pain, fatigue, anxiety, and depression. Treatment patterns …
Endometriosis is a chronic inflammatory condition affecting ~10% of reproductive-age individuals and contributing significantly to infertility, pain, and reduced quality of life. Since our 2020 review, new pharmacologic strategies, updated …
Deep endometriosis (DE) is a common disease in 15%-45% of childbearing-age women. Combined oral contraceptive pill (COCP) and dienogest have been used for decades to treat many forms of endometriosis …
Relugolix, an oral GnRH receptor antagonist, is effective in treating uterine myomas and endometriosis. However, concerns persist regarding the venous thromboembolism (VTE) risk associated with its combination with oral estradiol …
Dysmenorrhea is a common and disabling condition in women. We investigate the prevalence of endocrine dysmenorrhea treatment (EDT) and the use of pain medication in dysmenorrhea patients without surgically treated …